PE firm Darby invests in specialty pharmaceutical company Biopas

Date: 2019-02-15   Author: Pankaj Singh  Category: #news

PE firm Darby invests in specialty pharmaceutical company Biopas

The investment has been completed by Darby Private Equity via the DLAPDF III

Darby Overseas Investments Ltd., the private equity arm of Franklin Templeton Investments, has reportedly invested in Latin American specialty pharmaceutical company, Biopas (Pharma Consulting Group). Reportedly, the investment has been completed by Darby Private Equity by means of the DLAPDF III (Darby Latin American Private Debt Fund III).

Sources with knowledge of the matter cite that the latest move by Darby contributes to its history of successful investments in the Latin American region. Darby has emerged as a pioneer to bring private debt and private equity investments to the developing market regions, sources further affirmed. Details of the transaction have not yet been disclosed.

Established in 2002, Biopas has ever since extended into thirteen Latin American countries, holding its primary market in Colombia. The Pharmaceutical distribution firm has impactful presence in countries including Argentina, Peru, Chile and Ecuador. The firm apparently concentrates on in-licensing, sales and marketing of modern prescription pharmaceutical products, medical devices and cosmetics.

Pascal Forget, CEO & Co-founder at Biopas, was quoted to reveal that Darby’s investment will help Biopas get consolidated as a key regional contender in the healthcare space and will further allow it to maintain a leadership position in countries the company operates in. He went on to say that the investment is likely to help the company to grow sustainably and continue providing all products from its extensive portfolio, besides introducing new, life-altering medicines to Latin America.

According to Ignacio Aicardi, the Managing Director at Darby, the company is quite excited about collaborating with Biopas, with a purpose to transform patients’ lives in Latin America. The latest transaction is in line with Darby’s commitment to investment in companies across Latin America, with a successful track record, as well as efficient management, he further commented.

For the record, Biopas, headquartered in Panama, is operational in five key business units including the Central Nervous System (CNS) & Oncology, Immunology, Specialty Care, Dermatology and Rare Diseases.



About Author


Pankaj Singh linkdin-boxtwitter

Pankaj Singh

Pankaj Singh Develops content for Algosonline, Market Size Forecasters, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

Post Recommendents

Intelligent Process Automation(IPA) Market Covid-19 Impact In-Depth Industry Analysis 2026

Author: Ashwin Naphade

The research report on Intelligent Process Automation(IPA) market offers critical information such as the development trends, restraints, CAGR, revenue prospects, product type, application scope, competitive scenario, and COVID-19 impact.

<...


Passive Optical LAN (POL) market players to make profitable investments during 2021-2026

Author: Ashwin Naphade

Global Passive Optical LAN (POL) Market Report provides complete industry analysis, market outlook, size, growth, opportunities and forecast 2026. This report will assist in analyzing the current and future business trends, sales and revenue forec...


Research on Intelligent Machine Control System Market 2021: By Growing Rate, Type, Applications, Geographical Regions, and Forecast to 2026

Author: Ashwin Naphade

Intelligent Machine Control System market report is a comprehensive analysis of the growth dynamics and revenue inflows in this industry sphere over 2021-2026, inclusive of Covid-19 impact.

The latest research report on Intelligent Machi...